Ownership and insider activity for Johnson & Johnson (JNJ): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Price
| Price | $252.93 |
| Market Cap | $609.5B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Pinto Daniel E | A-Award | 113 | |
| 2026-09-08 | Woods Eugene A. | A-Award | 135 | |
| 2026-09-08 | HEWSON MARILLYN A | A-Award | 180 | |
| 2026-09-02 | Schmid Timothy | M-Exempt | 22,527 | $3.4M |
| 2026-09-02 | Schmid Timothy | M-Exempt | 11,070 | $1.5M |
| 2026-09-02 | Schmid Timothy | S-Sale | 22,527 | $6.2M |
| 2026-09-02 | Schmid Timothy | M-Exempt | 11,070 | $1.5M |
| 2026-09-02 | Schmid Timothy | M-Exempt | 22,527 | $3.4M |
| 2026-09-01 | Cavanaugh Thomas | |||
| 2026-09-01 | Cavanaugh Thomas |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.97B | $17.82B | $18.11B | $17.30B | $13.98B | $14.49B | $12.89B | $21.86B | $24.11B | $19.71B |
| Short-term Investments | $22.93B | $472.0M | $1.58B | $1.98B | $11.20B | $17.12B | $9.39B | $1.07B | $417.0M | $393.0M |
| Receivables | $11.70B | $13.49B | $14.10B | $14.48B | $13.58B | $18.98B | $16.91B | $14.87B | $18.93B | $17.18B |
| Inventory | $8.14B | $8.77B | $8.60B | $9.02B | $9.34B | $10.39B | $10.27B | $11.18B | $12.44B | $14.19B |
| Total Current Assets | $65.03B | $43.09B | $46.03B | $45.27B | $51.24B | $60.98B | $55.29B | $53.49B | $55.89B | $55.62B |
| Property, Plant & Equipment | $15.91B | $17.00B | $17.04B | $17.66B | $18.77B | $18.96B | $17.98B | $19.90B | $20.52B | $23.17B |
| Goodwill | $22.80B | $31.91B | $30.45B | $33.64B | $36.39B | $35.25B | $36.05B | $36.56B | $44.20B | $48.77B |
| Intangible Assets | $26.88B | $53.23B | $47.61B | $47.64B | $53.40B | $46.39B | $38.49B | $34.17B | $37.62B | $50.40B |
| Total Assets | $141.21B | $157.30B | $152.95B | $157.73B | $174.89B | $182.02B | $187.38B | $167.56B | $180.10B | $199.21B |
| Accounts Payable | $6.92B | $7.31B | $7.54B | $8.54B | $9.51B | $11.05B | $9.89B | $9.63B | $10.31B | $11.99B |
| Short-term Debt | $4.68B | $3.91B | $2.80B | $1.20B | $2.63B | $3.77B | $12.76B | $3.45B | $5.98B | $8.49B |
| Total Current Liabilities | $26.29B | $30.54B | $31.23B | $35.96B | $42.49B | $45.23B | $55.80B | $46.28B | $50.32B | $54.13B |
| Long-term Debt | $22.44B | $30.68B | $27.68B | $26.49B | $32.63B | $29.98B | $26.89B | $25.88B | $30.65B | $39.44B |
| Total Liabilities | $70.79B | $97.14B | $93.20B | $98.26B | $111.62B | $108.00B | $110.57B | $98.78B | $108.61B | $117.67B |
| Retained Earnings | $110.55B | $101.79B | $106.22B | $110.66B | $113.89B | $123.06B | $128.34B | $153.84B | $155.79B | $168.98B |
| Total Equity | $70.42B | $60.16B | $59.75B | $59.47B | $63.28B | $74.02B | $76.80B | $68.77B | $71.49B | $81.54B |
| Total Debt | $27.13B | $34.58B | $30.48B | $27.70B | $35.27B | $33.75B | $39.64B | $29.33B | $36.63B | $47.93B |
| Net Debt | -$14.78B | $16.29B | $10.79B | $8.41B | $10.08B | $2.14B | $17.36B | $6.41B | $12.11B | $27.83B |
| Working Capital | $38.74B | $12.55B | $14.80B | $9.31B | $8.74B | $15.75B | -$508.0M | $7.21B | $5.57B | $1.50B |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 1.03 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 4.66 |
Profitability
| Return on Equity | 32.87% |
| Return on Invested Capital | 13.71% |
| Return on Assets | 13.46% |
| Gross Margin | 67.88% |
| Operating Margin | 27.17% |
| Net Margin | 28.46% |
Related companies: ABBV · AMGN · AZN · GILD · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of JNJ: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks